News

X-ZELL is now officially partnering with Singapore’s DxD Hub.   Singapore, December 2018 – In a move that will accelerate the company's capabilities and scale up its commercialisation and product development processes, X-ZELL has partnered with Singapore’s...

Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has used the 2018 European Multidisciplinary Congress on Urological Cancers (EMUC18) in Amsterdam as a platform to present new insights into the origin and clinical utility of Circulating Endothelial Cells...

Singapore, November 2018 – X-ZELL  has been one of eight promising biotechnology start-ups selected to exhibit at the inaugural A*CCELERATE NOW exhibition in Singapore. The landmark event – held in a move to celebrate the re-branding of ETPL, the commercialisation arm...

Amsterdam, November 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has been invited to join the 2018 European Multidisciplinary Congress on Urological Cancers (#EMUC18) in Amsterdam next month as a plenary speaker. Dr Bhakdi’s addition to the Congress’ high-profile program...

Singapore, October 2018 – X-ZELL, only recently named one of Asia’s 20 most innovative health tech start-ups, is coming to Singapore. According to X-ZELL CEO, Dr Sebastian Bhakdi, the rare cell detection specialist’s global head office is slated to move from Bangkok...

Singapore, September 2018 – Galen Growth, a Singapore-based analytics and advisory firm specialising in cutting-edge healthcare technology, has named X-ZELL as one of the 20 most innovative health technology start-ups in Asia. Selected to feature in the 2018 edition...

Oxford, August 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, has published new research into the utility of tumour-associated Circulating Endothelial Cells (tCEC) for the detection of early-stage prostate cancer. His latest abstract – titled Tumor‐Derived Circulating...

Bangkok, July 2018 – After successfully completing a series of clinical trials across Southeast Asia, atypical cell detection specialist X-ZELL is now making the company’s patented Cryoimmunostaining™ technology available to research organisations around the globe....

Brisbane, July 2018 – X-ZELL CEO, Dr Sebastian Bhakdi, will use the upcoming Asia-Pacific Prostate Cancer Conference (APCC) in Brisbane next month as a platform to reveal “exciting new insights” into early prostate cancer detection. According to Dr Bhakdi, his...

Singapore, June 2018 – The Department of Urology at Singapore’s National University Hospital and X-ZELL have signed a Letter of Intent (LOI) to jointly conduct a prospective, blinded study evaluating the utility of X-ZELL Prostate™ for early prostate cancer detection....